Fig. 2

A case presentation (complete response, long-term alive, no recurrence). A 72-year-old man, with liver cirrhosis Child–Pugh class A (non-HBV, non-HCV related), was diagnosed as having a 12-cm HCC in left lobe of liver with classical enhancement pattern and involvement of left portal vein by CT scan in August 2016, clinically staged as cT3bN0M0, BCLC stage C. High alpha-fetoprotein (AFP) up to 160.1 ng/ml was noted. TACE failed with only partial obliteration of tumor vessels. He was then eligible for this phase I trial. He received RT with 45 Gy in 15 fractions plus axitinib 1 mg twice daily for 2 months. The patient tolerated the treatment well. At 3 months after RT initiation, follow-up CT scan revealed complete response of the tumor, and AFP decreased to 1.9 ng/ml. In 2020, the patient is still regularly followed up without recurrence